The 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias were developed by the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), with contributions from the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). The guidelines aim to assist healthcare professionals in selecting the best management strategies for patients with dyslipidaemias, considering the impact on outcomes and the risk-benefit ratio of diagnostic and therapeutic approaches. The guidelines are based on the best available scientific evidence and are intended for personal and educational use only, with no commercial use authorized. They emphasize the importance of total cardiovascular risk assessment, lifestyle modifications, and drug treatments for managing dyslipidaemias. The guidelines also address specific conditions such as familial dyslipidaemias, diabetes, and chronic kidney disease, and provide recommendations for different clinical settings. The guidelines are accompanied by a list of abbreviations, a preamble, and a table of contents. The guidelines emphasize the importance of cost-effectiveness in prevention and the need for a lifetime approach to cardiovascular risk management. They also highlight the importance of risk stratification and the use of risk estimation charts to guide treatment decisions. The guidelines are intended to be used in conjunction with other recommendations and guidelines from public health authorities, and they emphasize the importance of individualized care and patient consultation. The guidelines are available on the ESC website and are regularly updated to reflect the latest scientific evidence.The 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias were developed by the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), with contributions from the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). The guidelines aim to assist healthcare professionals in selecting the best management strategies for patients with dyslipidaemias, considering the impact on outcomes and the risk-benefit ratio of diagnostic and therapeutic approaches. The guidelines are based on the best available scientific evidence and are intended for personal and educational use only, with no commercial use authorized. They emphasize the importance of total cardiovascular risk assessment, lifestyle modifications, and drug treatments for managing dyslipidaemias. The guidelines also address specific conditions such as familial dyslipidaemias, diabetes, and chronic kidney disease, and provide recommendations for different clinical settings. The guidelines are accompanied by a list of abbreviations, a preamble, and a table of contents. The guidelines emphasize the importance of cost-effectiveness in prevention and the need for a lifetime approach to cardiovascular risk management. They also highlight the importance of risk stratification and the use of risk estimation charts to guide treatment decisions. The guidelines are intended to be used in conjunction with other recommendations and guidelines from public health authorities, and they emphasize the importance of individualized care and patient consultation. The guidelines are available on the ESC website and are regularly updated to reflect the latest scientific evidence.